{"id":15559,"date":"2022-01-21T18:49:41","date_gmt":"2022-01-21T13:19:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=15559"},"modified":"2022-02-03T17:35:55","modified_gmt":"2022-02-03T12:05:55","slug":"beta-thalassemia-treatment-market-insights-challenges-and-solutions","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions","title":{"rendered":"Beta Thalassemia Treatment &#8211; Insights Into the Challenges &#038; Solutions"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f4e2a816594\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f4e2a816594\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#Beta_Thalassaemia_Pathophysiology\" >Beta Thalassaemia Pathophysiology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#Beta_Thalassaemia_Treatment_Market_Outlook\" >Beta Thalassaemia Treatment Market Outlook<\/a><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#As_per_DelveInsight_Analysis_Anticipated_United_States_BetaThalassemia_Market_Size_Will_Reach_Upto_USD_7451_million_by_2032\" >As per DelveInsight Analysis, Anticipated United States #BetaThalassemia Market Size Will Reach Upto USD 745.1 million by 2032<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#Market_Leaders_in_the_Making\" >Market Leaders in the Making<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#Expected_Roadblocks\" >Expected Roadblocks<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#Different_Treatments_For_Beta_Thalassemia\" >Different Treatments For Beta Thalassemia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#The_Road_Ahead_For_Beta_Thalassaemia\" >The Road Ahead For Beta Thalassaemia<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n<p>Beta Thalassemia (\u03b2-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. General occurrence of severe and untreated Beta Thalassemia symptoms include severe anemia, with an Hb level of 3\u22126 g\/dL, massive hepatosplenomegaly, severe growth retardation, and bony deformities. Beta Thalassemia treatment therapy involves regular blood transfusions, iron chelation, bone marrow transplant and novel gene therapy options. Surgery for spleen or gallbladder removal serves as the last curative treatment option.<\/p>\n\n\n\n<p>People with Beta Thalassemia major or intermediate usually have a buildup of iron, either from the disease itself or from repeated blood transfusions. Excess iron can damage the heart, liver, and endocrine system. People with the minor form of Beta Thalassaemia have small red blood cells but no symptoms.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184003\/Beta-Thalassemia-Epidemiological-Insights-01-1.png\" alt=\"\" class=\"wp-image-15622\" width=\"497\" height=\"241\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184003\/Beta-Thalassemia-Epidemiological-Insights-01-1.png 994w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184003\/Beta-Thalassemia-Epidemiological-Insights-01-1-300x145.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184003\/Beta-Thalassemia-Epidemiological-Insights-01-1-150x73.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184003\/Beta-Thalassemia-Epidemiological-Insights-01-1-768x372.png 768w\" sizes=\"(max-width: 497px) 100vw, 497px\" \/><figcaption> <strong>Beta Thalassemia Epidemiology<\/strong> <\/figcaption><\/figure><\/div>\n\n\n\n<p>In order to determine <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-b-thal-epidemiology-forecast\">Beta Thalassemia prevalent population<\/a> in the 6MM (United States, Germany, France, Spain, Italy, and the United Kingdom), DelveInsight considered and compared data from various studies and organizational databases. We also collected different KOL views and expert opinions to cover the geographical differences in Beta Thalassemia epidemiology across the 6MM.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-b-thal-epidemiology-forecast\">total prevalent cases of Beta Thalassemia<\/a> in the 6MM were found to be <strong>12,536<\/strong> in <strong>2020<\/strong>. Italy accounted for the highest number of cases, followed by the United States, Germany, UK, France, and Spain. According to DelveInsight\u2019s estimates, among the European countries, <strong>Italy<\/strong> had the highest number of prevalent cases of Beta Thalassemia (<strong>7,123<\/strong>) in 2020 and is expected to reach <strong>7,058 <\/strong>by 2030.At the same time, <strong>Spain<\/strong> had the lowest number of prevalent cases (<strong>275<\/strong>)in 2020, which as per DelveInsight\u2019s estimates, are expected to reach <strong>280 <\/strong>cases by 2032.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-b-thal-epidemiology-forecast\">\u201cAs per DelveInsight assessments, <strong>EU5 <\/strong>countries together accounted for <strong>10,522 cases.\u201d<\/strong><\/a><\/p><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-beta-thalassaemia-pathophysiology\"><span class=\"ez-toc-section\" id=\"Beta_Thalassaemia_Pathophysiology\"><\/span><strong>Beta Thalassaemia Pathophysiology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Beta Thalassaemia is an inherited blood disorder caused due to genetic modification on Chromosome 11. The major risk factors include \u201cFamily history of the disorder\u201d and \/or \u201cAsian, Chinese, Mediterranean, or African American ethnicity.\u201d These can become so severe that they may cause organ failure, which is when your organs stop working effectively.<strong> <\/strong>Beta Thalassaemia inheritance results from various mutations (over 200 disease-causing mutations have been identified) or, rarely, deletions of the beta-globin gene (HbB) on chromosome 11. These mutations are primarily \u2018point mutations\u2019 that affect transcriptional control, translation, and splicing of the HbB gene and gene product.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21183845\/The-Rare-Blood-Disease-Beta-Thalassemia-Caused-Due-to-Mutation-on-Chromosome-11-01.png\" alt=\"\" class=\"wp-image-15619\" width=\"552\" height=\"325\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21183845\/The-Rare-Blood-Disease-Beta-Thalassemia-Caused-Due-to-Mutation-on-Chromosome-11-01.png 552w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21183845\/The-Rare-Blood-Disease-Beta-Thalassemia-Caused-Due-to-Mutation-on-Chromosome-11-01-300x177.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21183845\/The-Rare-Blood-Disease-Beta-Thalassemia-Caused-Due-to-Mutation-on-Chromosome-11-01-150x88.png 150w\" sizes=\"(max-width: 552px) 100vw, 552px\" \/><figcaption> <strong>Mutations Due to Beta Thalassemia<\/strong> <\/figcaption><\/figure><\/div>\n\n\n\n<p>There are three main Beta Thalassaemia types including; Thalassaemia Major (variably referred to as \u201cCooley\u2019s Anemia\u201d and \u201cMediterranean Anemia), Thalassaemia Intermediate, and Thalassaemia Minor (also called \u201cBeta Thalassemia carrier,\u201d \u201cBeta Thalassemia trait\u201d or \u201cheterozygous Beta Thalassemia\u201d).<\/p>\n\n\n\n<p>Disease associations and other organized programs for Beta Thalassemia patients are established in most regions. Some prominent ones include the <strong>Thalassemia Support Foundation, Thalassemia International Federation, and The Cooley\u2019s Anemia Foundation<\/strong>,<strong> <\/strong>among others. All of these provide opportunities to map the patients and improve their access to <a href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia\">innovative Beta Thalassemia treatment and outcomes<\/a>. Soon, establishing country-wide registries in cooperation with these centers may also help tackle the disease further.<\/p>\n\n\n\n<p>Transfusion-dependence is essential in distinguishing the various Thalassemia phenotypes and their severity. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-market-forecast\">diagnosis of Beta Thalassemia major<\/a> entails a lifelong regular transfusion requirement for survival (TDT \u2013 Transfusion dependent thalassemia). Globally, ~100,000 patients currently receive regular transfusions for Beta Thalassemia. Blood transfusion exposes patients to several risks (blood-borne infection, alloimmunization, and iron overload), necessitating proper clinical practice guidelines for the management of TDT.<\/p>\n\n\n\n<p>Severe <a href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia\">Beta Thalassemia major patients require lifelong therapy<\/a> to prevent and manage the clinical consequences of the disease. Long-term adherence to treatment is essential. Comprehensive management guidelines for both TDT and NTDT have been developed by the Thalassemia International Federation and are widely available. Current management strategies for TDT include blood transfusion, iron chelation, splenectomy (less common than in the past), and HSCT for a subset of patients.<\/p>\n\n\n\n<p>The other medications used for <a href=\"https:\/\/www.delveinsight.com\/blog\/how-gene-therapy-is-changing-the-beta-thalassemia-treatment-outlook\">Beta Thalassemia treatment<\/a> include <strong>deferiprone (DFP), deferasirox (DFX), and desferrioxamine (DFO).<\/strong> Treatment with <strong>DFX and DFP<\/strong> is preferred due to their cost-effectiveness and ease of administration (oral). <strong>DFO<\/strong>, on the other hand, is administered subcutaneously, intravenously, or occasionally intramuscularly. The goal of Beta Thalassemia treatment is to maintain a hemoglobin level of 9\u201310.5 g\/dL, which has been shown to promote normal growth, suppress bone marrow activity, and minimize iron accumulation.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Beta_Thalassaemia_Treatment_Market_Outlook\"><\/span><strong>Beta Thalassaemia Treatment Market Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>According to DelveInsight, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-market-forecast\">lion\u2019s share of the Beta Thalassemia market<\/a> by the end of the forecast period (2019\u20132032) is likely to be captured by the United States by reaching <strong>USD 745.1 million<\/strong> by 2032 from <strong>USD 74.9 million<\/strong> in 2019.&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21182348\/Beta-Thalassemia-Market-Insights-and-Market-Forecast-01-1.png\" alt=\"Beta-thalessemia-market\" class=\"wp-image-15601\" width=\"602\" height=\"622\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21182348\/Beta-Thalassemia-Market-Insights-and-Market-Forecast-01-1.png 1204w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21182348\/Beta-Thalassemia-Market-Insights-and-Market-Forecast-01-1-290x300.png 290w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21182348\/Beta-Thalassemia-Market-Insights-and-Market-Forecast-01-1-991x1024.png 991w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21182348\/Beta-Thalassemia-Market-Insights-and-Market-Forecast-01-1-145x150.png 145w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21182348\/Beta-Thalassemia-Market-Insights-and-Market-Forecast-01-1-768x794.png 768w\" sizes=\"(max-width: 602px) 100vw, 602px\" \/><figcaption><strong>Beta Thalassemia Market Analysis<\/strong><\/figcaption><\/figure><\/div>\n\n\n\n<p>In 2019, among EU5, <strong>Italy <\/strong>accounted for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-market-forecast\">largest Beta Thalassemia market size<\/a> (<strong>USD<\/strong> <strong>184.3 million<\/strong>), followed by <strong>Germany<\/strong> with <strong>USD 38.9 million<\/strong>,<strong> <\/strong>whereas <strong>Spain <\/strong>accounted for the smallest (<strong>USD 7.1 million<\/strong>).<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-market\">future of the Beta Thalassemia treatment market<\/a> looks promising with new and emerging therapies such as<strong> CTX001 <\/strong>by <strong>CRISPR Therapeutics\/Vertex Pharmaceuticals, Mitapivat (AG-348) <\/strong>by <strong>Agios Pharmaceuticals, 9.4 IMR-687 by Imara Inc.<\/strong>, among others.<\/p>\n\n\n\n<div class=\"px-5 py-4 border my-4\"> <h4 style=\"color:#2251ff;font-size:20px;line-height: 2;\"><span class=\"ez-toc-section\" id=\"As_per_DelveInsight_Analysis_Anticipated_United_States_BetaThalassemia_Market_Size_Will_Reach_Upto_USD_7451_million_by_2032\"><\/span><i>As per DelveInsight Analysis, Anticipated United States #BetaThalassemia Market Size Will Reach Upto USD 745.1 million by 2032<\/i><span class=\"ez-toc-section-end\"><\/span><\/h4> <div class=\"d-flex justify-content-end\"> <a class=\"twitter-share-button\" href=\"https:\/\/twitter.com\/intent\/tweet\" data-size=\"large\" data-text=\"As per DelveInsight Analysis, Anticipated United States #BetaThalassemia Market Size Will Reach Upto USD 745.1 million by 2032 #Marketresearch #healthcare\" data-url=\" https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-market-forecast\" data-hashtags=\"biosimilars,delveinsight\" data-via=\"delve_insight\" data-related=\"twitterapi,twitter\" style=\"color:#2251ff\"> Tweet This <\/a> <\/div> <\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-leaders-in-the-making\"><span class=\"ez-toc-section\" id=\"Market_Leaders_in_the_Making\"><\/span><strong>Market Leaders in the Making<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>With a cornucopia of <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-pipeline-insight\">drugs in the Beta Thalassemia pipeline<\/a>, the market size is projected to increase. Among the emerging therapies, the most promising ones include <strong>CTX001 \u2013 a Phase II\/III Cell replacement therapy<\/strong>, <strong>Mitapivat \u2013 a Phase III Pyruvate Kinase stimulant<\/strong>, <strong>Zynteglo- Phase III Gene therapy (US)<\/strong>, among others. Other promising therapies include <strong>IMR-687 (Imara Inc.), Sapablursen (Ionis Pharmaceuticals), DST-0509 (DisperSol Technology), SLN 124 (Silence Therapeutics),<\/strong> and many more.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184132\/Key-Players-Working-in-the-Beta-Thalassemia-Market-01-01.png\" alt=\"\" class=\"wp-image-15624\" width=\"708\" height=\"286\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184132\/Key-Players-Working-in-the-Beta-Thalassemia-Market-01-01.png 708w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184132\/Key-Players-Working-in-the-Beta-Thalassemia-Market-01-01-300x121.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21184132\/Key-Players-Working-in-the-Beta-Thalassemia-Market-01-01-150x61.png 150w\" sizes=\"(max-width: 708px) 100vw, 708px\" \/><figcaption> <strong>Pharma Players in the Beta Thalassemia Market<\/strong> <\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Expected_Roadblocks\"><\/span><strong>Expected Roadblocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>At present, there remains a <strong>large degree of disparity in blood donation levels<\/strong> worldwide. Australia, Europe, and North America have the highest donation rates. In recent years, there has been a rise in donation rates, but the demand for transfusions in low-income countries exceeds the current supply. Around the globe, more than 22,500 patients with transfusion-dependent Beta Thalassemia die each year due to insufficient blood supply. Because of this, service providers are often required to seek out alternative blood sources, such as paid donors or family members.<\/p>\n\n\n\n<p>However, international organizations such as WHO and the Red Cross discourage paid blood donation. Offering money may attract unhealthy donors, leading to anemia due to frequent donations, and drive altruistic donors away, resulting in fewer donors overall. Better awareness programs on blood donation may help improve the rates of blood donations.&nbsp;<\/p>\n\n\n\n<p>The<a href=\"https:\/\/www.delveinsight.com\/report-store\/thalassemia-epidemiology-forecast\"><strong>changing patterns of Thalassemia prevalence<\/strong><\/a> in different parts of the world are mainly affected by changes in the number of births of new patients. They are largely influenced by prevention programs, population migration, and improved survival of \u03b2\u2010thalassemia patients. Historically, \u03b2\u2010thalassemia is highly prevalent in the Mediterranean, Middle East, and Southeast Asia, and migration patterns have increased the prevalence of this hemoglobinopathy in North America and Northern European countries. Notably, the increasing prevalence in these countries has increased the burden on healthcare systems. As long as migration to these regions continues, for example, due to economic, social, or environmental reasons, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-b-thal-epidemiology-forecast\">prevalence of \u03b2\u2010thalassemia<\/a> will continue to increase until the point is reached where large\u2010scale preventive measures are implemented. The COVID\u201019 pandemic has significantly diminished migration, but its long\u2010term consequences remain to be seen.&nbsp;<\/p>\n\n\n\n<p>Another service essential for accurate diagnosis and monitoring of Beta Thalassemia patients is good laboratory support. TIF and other guidelines clearly state the need for diagnostic workup before the first transfusion, and they provide a timetable and a list of parameters required for patient monitoring throughout their life. Such parameters determine treatment decisions and must therefore be followed. Yet thousands of patients are treated according to a Hb and ferritin check performed at irregular intervals. Proper monitoring will give early warning of complications and has allowed lifesaving interventions. Universal standards for specialized tests such as Magnetic resonance imaging for the quantitation of iron load are still pending in many parts of the world.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Different_Treatments_For_Beta_Thalassemia\"><\/span><strong>Different Treatments For Beta Thalassemia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Iron is present in transfused blood, which is rarely eliminated by the body. On a typical blood transfusion schedule, patients with thalassemia collect iron at a rate of 0.3\u20130.6 mg\/kg of body weight every day. At levels of 12\u201324 g of total body iron, <strong>excess iron becomes toxic and accumulates in the heart, liver, and endocrine system<\/strong>. <a href=\"https:\/\/www.delveinsight.com\/blog\/dilated-cardiomyopathy-market-dcm-market\">Cardiomyopathy<\/a> can be caused by too much iron, and untreated patients may die of heart failure before they reach the age of 20. Even in the absence of <a href=\"https:\/\/www.delveinsight.com\/blog\/evolution-in-hepatitis-b-and-c-virus\">chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections<\/a>, iron excess raises the <a href=\"https:\/\/www.delveinsight.com\/report-store\/liver-fibrosis-market\">risk of liver fibrosis<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/cirrhosis-pipeline-insight\">cirrhosis<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/blog\/driving-factors-boosting-the-hepatocellular-carcinoma-market\">hepatocellular cancer<\/a>. <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypogonadism-market\">Hypogonadism<\/a>, growth retardation, delayed puberty, <a href=\"https:\/\/www.delveinsight.com\/report-store\/female-infertility-market\">infertility<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetes-market\">diabetes<\/a>, and <a href=\"https:\/\/www.delveinsight.com\/report-store\/hypothyroidism-market\">hypothyroidism<\/a> are all possible side effects of iron overload. Excess iron must be removed to avoid consequences from iron overload, and ICT should begin within a year of starting frequent blood transfusions. ICT increases overall survival and lowers the incidence of iron overload consequences such as heart disease, short stature, and endocrine problems. In the United Kingdom, most patients now undergo ICT with either deferasirox or deferiprone monotherapy or combination ICT (typically subcutaneous desferrioxamine and deferiprone), which has significantly impacted how patients and others around them view and feel thalassemia.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/hematopoietic-stem-cells-transplantation\"><strong>Allogeneic hematopoietic stem cell transplantation (HSCT)<\/strong><\/a> is the only available curative treatment for Beta Thalassemia major (b-TM) patients. In recent years, the increased number of transplants has further upsurged with an increased <a href=\"https:\/\/www.delveinsight.com\/report-store\/graft-versus-host-disease-gvhd-epidemiology-forecast\">incidence of Graft Versus Host Disease (GvHD)<\/a>. At the time of the survey, a higher incidence of comorbidities with GVHD was recorded as compared to those without it. Mortality in the first 10 years following HSCT was significantly higher than conventional treatment, with nearly 50% of the mortality being driven by acute GvHD as quoted in literature. Unfortunately, the incidence of acute GvHD following transplantation has not significantly improved over the decades, and hence lowering the rate of acute GvHD-related mortality remains an unmet goal.&nbsp;<\/p>\n\n\n\n<p>Patients with transfusion-dependent Thalassemia must be managed with blood transfusions and <strong>iron chelation therapy<\/strong> for the rest of their lives. <strong>Iron overload<\/strong> complications can result in severe morbidity and mortality, and it is widely established that the chronic management of this disease places a significant financial and time burden on patients. Patients with TD-thalassemia had considerably greater healthcare resource utilization, prescription expenditures, and total costs than matched controls and were forced to contact their healthcare provider frequently, which hampered their quality of life and work productivity.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong><em>HAVE YOU READ? \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/how-gene-therapy-is-changing-the-beta-thalassemia-treatment-outlook\"><strong><em>How Gene therapy is changing the Beta-thalassemia Treatment outlook?<\/em><\/strong><\/a><strong><em>\u201d<\/em><\/strong><\/p><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-road-ahead-for-beta-thalassaemia\"><span class=\"ez-toc-section\" id=\"The_Road_Ahead_For_Beta_Thalassaemia\"><\/span><strong>The Road Ahead For Beta Thalassaemia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The futuristic approach for Beta Thalassemia treatment will depend on the increased availability of iron chelation, \u03b3-globin induction, blood transfusion, allogeneic bone marrow transplantation, and <a href=\"https:\/\/www.delveinsight.com\/blog\/how-gene-therapy-is-changing-the-beta-thalassemia-treatment-outlook\">gene therapy for Beta Thalassemia<\/a> in developed as well as more in the under-developed and low-income countries. The next few years will be very critical for the rise of Beta Thalassemia treatment measures to be adopted, with enormous potential of gene transfer methods for Beta Thalassemia patients, in regard to both the safety and efficacy determinants.<\/p>\n\n\n\n<p>As per DelveInsight estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/beta-thalassemia-market-forecast\">Beta Thalassemia market landscape<\/a> looks promising with greater advances in diagnosis and treatments translating into a better quality of life and improved survival. The entry of the novel therapies necessitates collaboration among academia, life-sciences companies, funding, regulatory agencies, decision-makers, and caregivers to attain better healthcare.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><a href=\"https:\/\/www.delveinsight.com\/sample-request\/beta-thalassemia-market-forecast\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175557\/DelveInsights-Beta-Thalassemia-Market-Insights-2032-report-highlights-the-market-trends-historical-and-forecasted-epidemiology-and-key-players-in-the-Beta-Thalassemia-Market.-1.gif\" alt=\"\" class=\"wp-image-15574\" width=\"1024\" height=\"256\"\/><\/a><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1642765662529\"><strong class=\"schema-faq-question\"><strong>What is Beta Thalassemia disease?<\/strong><\/strong> <p class=\"schema-faq-answer\">Beta Thalassemia is an inherited blood disorder that reduces the production of hemoglobin. A low level of hemoglobin usually leads to a lack of oxygen in many parts of the body.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1642765695783\"><strong class=\"schema-faq-question\"><strong>Is Beta Thalassemia fatal?<\/strong><\/strong> <p class=\"schema-faq-answer\">Yes, Beta Thalassemia can be fatal with severe life-threatening symptoms and severe anemia, but with proper and regular treatments including blood transfusions, early deaths can be prevented.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1642765717890\"><strong class=\"schema-faq-question\"><strong>Can Beta Thalassemia be cured?<\/strong><\/strong> <p class=\"schema-faq-answer\">Currently, the only complete cure is Bone Marrow Transplant for Beta Thalassemia, but it is possible for only a small proportion of patients.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beta Thalassemia (\u03b2-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. General occurrence of severe and untreated Beta Thalassemia symptoms include [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":15572,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[2650,19037,19038,19039,17906,17830],"industry":[17225],"therapeutic_areas":[17238,17233],"class_list":["post-15559","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-beta-thalassemia-2","tag-beta-thalassemia-market-3","tag-beta-thalassemia-pipeline-2","tag-beta-thalassemia-pipeline-drugs","tag-beta-thalassemia-therapies","tag-beta-thalassemia-treatment","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Beta Thalassemia Treatment Market Outlook, Emerging Drugs, Companies<\/title>\n<meta name=\"description\" content=\"Beta Thalassemia treatment market looks promising with advances in diagnosis and treatments translating into better quality of life.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beta Thalassemia Treatment Market Outlook, Emerging Drugs, Companies\" \/>\n<meta property=\"og:description\" content=\"Beta Thalassemia treatment market looks promising with advances in diagnosis and treatments translating into better quality of life.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-21T13:19:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-03T12:05:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175325\/What-Is-The-Rare-Beta-Thalassemia-Blood-Disorder.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beta Thalassemia Treatment Market Outlook, Emerging Drugs, Companies","description":"Beta Thalassemia treatment market looks promising with advances in diagnosis and treatments translating into better quality of life.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions","og_locale":"en_US","og_type":"article","og_title":"Beta Thalassemia Treatment Market Outlook, Emerging Drugs, Companies","og_description":"Beta Thalassemia treatment market looks promising with advances in diagnosis and treatments translating into better quality of life.","og_url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-01-21T13:19:41+00:00","article_modified_time":"2022-02-03T12:05:55+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175325\/What-Is-The-Rare-Beta-Thalassemia-Blood-Disorder.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions","url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions","name":"Beta Thalassemia Treatment Market Outlook, Emerging Drugs, Companies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175325\/What-Is-The-Rare-Beta-Thalassemia-Blood-Disorder.png","datePublished":"2022-01-21T13:19:41+00:00","dateModified":"2022-02-03T12:05:55+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Beta Thalassemia treatment market looks promising with advances in diagnosis and treatments translating into better quality of life.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765662529"},{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765695783"},{"@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765717890"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175325\/What-Is-The-Rare-Beta-Thalassemia-Blood-Disorder.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175325\/What-Is-The-Rare-Beta-Thalassemia-Blood-Disorder.png","width":772,"height":482,"caption":"what-is-the-future-of-beta-thalassemia-market"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765662529","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765662529","name":"What is Beta Thalassemia disease?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Beta Thalassemia is an inherited blood disorder that reduces the production of hemoglobin. A low level of hemoglobin usually leads to a lack of oxygen in many parts of the body.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765695783","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765695783","name":"Is Beta Thalassemia fatal?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Yes, Beta Thalassemia can be fatal with severe life-threatening symptoms and severe anemia, but with proper and regular treatments including blood transfusions, early deaths can be prevented.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765717890","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/beta-thalassemia-treatment-market-insights-challenges-and-solutions#faq-question-1642765717890","name":"Can Beta Thalassemia be cured?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Currently, the only complete cure is Bone Marrow Transplant for Beta Thalassemia, but it is possible for only a small proportion of patients.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/21175325\/What-Is-The-Rare-Beta-Thalassemia-Blood-Disorder-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beta thalassemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beta Thalassemia Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beta Thalassemia pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beta Thalassemia pipeline drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beta Thalassemia Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Beta Thalassemia Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Beta thalassemia<\/span>","<span class=\"advgb-post-tax-term\">Beta Thalassemia Market<\/span>","<span class=\"advgb-post-tax-term\">Beta Thalassemia pipeline<\/span>","<span class=\"advgb-post-tax-term\">Beta Thalassemia pipeline drugs<\/span>","<span class=\"advgb-post-tax-term\">Beta Thalassemia Therapies<\/span>","<span class=\"advgb-post-tax-term\">Beta Thalassemia Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jan 21, 2022","modified":"Updated on Feb 3, 2022"},"absolute_dates_time":{"created":"Posted on Jan 21, 2022 6:49 pm","modified":"Updated on Feb 3, 2022 5:35 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15559","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=15559"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15559\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/15572"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=15559"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=15559"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=15559"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=15559"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=15559"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}